重新思考转甲状腺素蛋白淀粉样心肌病的疾病进展:迈向机制特异性监测与治疗反应评估
本文提出转甲状腺素蛋白淀粉样心肌病的疾病进展应理解为淀粉样前体蛋白生物学、淀粉样负荷和器官反应三个生物学领域的相互作用,而非仅依赖反映下游表现的临床、生物标志物和功能指标。随着稳定剂、基因沉默等机制特异性疗法的出现,监测策略需从追踪疾病后果转向测量被靶向的生物学过程,以实现精准治疗指导。
要点
- 疾病进展应分为前体蛋白生物学、淀粉样负荷和器官反应三个相互关联的领域。
- 现有进展定义主要反映下游表现,与机制特异性疗法的靶点不匹配。
- 未来监测需同时精确测量疾病严重度和生物学过程,以指导个体化治疗。
核心结论
- 随着治疗日益机制特异性,监测策略必须从追踪疾病后果转向测量被靶向的生物学过程。
研究设计与样本
- 本文为概念性综述,未报告系统检索范围或样本量。
主要发现
- 疾病进展可理解为淀粉样前体蛋白生物学、淀粉样负荷和器官反应三个生物学领域的相互作用,三者可独立演变、对预后贡献不同且对治疗反应各异。
临床怎么用
- 临床监测应同时精确评估疾病严重度和疾病生物学,以支持机制特异性治疗指导和个体化护理。
局限性
- 本文为概念框架,未提供具体生物标志物阈值或临床验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic landscape of transthyretin amyloid cardiomyopathy has evolved rapidly, with the introduction of transthyretin stabilizers and gene-silencing therapies, together with the development of investigational genome-editing approaches and amyloid-depleting therapies. These therapeutic classes target distinct biological mechanisms underlying disease progression. However, current definitions of disease progression continue to rely predominantly on clinical, biomarker, and functional measures that reflect downstream manifestations of disease rather than the specific biological processes targeted by these therapies. As therapies become increasingly mechanism-specific, a more biologically informed framework for understanding disease progression and treatment response is needed. We propose that disease progression in transthyretin amyloid cardiomyopathy can be understood as the interaction of 3 biologically distinct, yet highly interconnected, domains: amyloid precursor protein biology, amyloid burden, and organ response. These domains continuously influence one another throughout the disease course; however, distinguishing them conceptually provides a biological framework that aligns disease progression with therapeutic mechanism and biomarker development. The first domain encompasses production, stability, and amyloidogenicity of the precursor protein and represents the fundamental driver of ongoing amyloid formation. The second reflects the cumulative burden of deposited amyloid within tissues, which serves as both a determinant of prognosis and a direct therapeutic target. The third comprises the consequences of amyloid deposition, including myocardial remodeling, neurohormonal activation, cardiorenal dysfunction, and the clinical manifestations of heart failure. These domains may evolve independently, contribute differently to prognosis, and respond differently to therapy. Ultimately, the future of disease monitoring in cardiac amyloidosis lies in both measuring disease severity more precisely and defining disease biology more accurately. Together, these complementary approaches have the potential to enable mechanism-specific therapeutic guidance and truly personalized care. As treatments become increasingly mechanism-specific, monitoring strategies must evolve from tracking the consequences of disease to measuring the biological processes being targeted. The greatest advances are likely to come from biomarkers that quantify precursor protein biology, amyloid burden, and organ response. This forward-looking conceptual framework provides a conceptual foundation for aligning disease biology, therapeutic mechanisms, and monitoring strategies with the ultimate goal of enabling precision therapeutic guidance for patients with cardiac amyloidosis.
引用
- Fontana M, Solomon SD, Hawkins PN, et al. Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy: Toward Mechanism-Specific Monitoring and Therapeutic Response Assessment. J Am Coll Cardiol. 2026. PMID: 42584380. doi:10.1016/j.jacc.2026.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。